Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Immunomedics, Takeda deal

Immunomedics disclosed in its fiscal 3Q13 earnings for the period ended March 31 that Takeda's Nycomed company

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE